Nisoldipine — Membership Pricing
Nisoldipine is not confirmed for no-additional-cost pricing. Membership pricing may be available; confirm the price with the dispensing pharmacy.
Nisoldipine Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Membership pricing may be available |
| Typical Retail | $55.00 |
Membership pricing may be available; confirm the price with the dispensing pharmacy.
About Nisoldipine
Nisoldipine is a prescription medication. Ask your doctor if Nisoldipine is right for you.
How to Check Nisoldipine Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Nisoldipine at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Heart & Cardiovascular
About Nisoldipine
High blood pressure is a silent threat, but medications like nisoldipine can help keep it in check. This calcium channel blocker is a powerful tool in cardiovascular health management. Understanding your treatment options and how to afford them is crucial. With TheDrugClub, you can access significant savings on prescriptions like nisoldipine, making your health journey more manageable and less costly.
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.
What Nisoldipine is approved for (FDA label)
Nisoldipine extended-release tablets are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
Source: Read the full FDA label on DailyMed. Label effective date: June 8, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Nisoldipine (FDA label)
ADVERSE EXPERIENCES More than 6,000 patients world-wide have received nisoldipine in clinical trials for the treatment of hypertension, either as the immediate release or the nisoldipine extended release formulation. Of about 1,500 patients who received nisoldipine extended-release tablets in hypertension studies, about 55% were exposed for at least 2 months and about one third were exposed for over 6 months, the great majority at doses equivalent to 17 mg and above. Nisoldipine extended-release tablets are generally well-tolerated. In the U.S. clinical trials of nisoldipine extended-release tablets in hypertension, 10.9% of the 921 nisoldipine extended-release tablets patients discontinued treatment due to adverse events compared with 2.9% of 280 placebo patients.
Source: FDA prescribing information (DailyMed). Set ID: a52b773a-44f9-442f-a4be-39f79a558bd2. SPL document ID: cef2c469-9a1b-46f3-b08f-57ea2876311f. Label effective date: June 8, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Nisoldipine (FDA label)
Nisoldipine extended-release tablets are contraindicated in patients with known hypersensitivity to dihydropyridine calcium channel blockers.
Source: FDA prescribing information (DailyMed). Set ID: a52b773a-44f9-442f-a4be-39f79a558bd2. SPL document ID: cef2c469-9a1b-46f3-b08f-57ea2876311f. Label effective date: June 8, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Nisoldipine (FDA label)
A 30 to 45% increase in AUC and C max of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily. Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15 to 20%). No pharmacodynamic effects of either histamine H2 receptor antagonist were observed. CYP3A4 inhibitors and inducers Nisoldipine is substrate of CYP3A4 and coadministration of nisoldipine extended-release tablets with any known inducer or inhibitor of CYP3A4 should be avoided in general. Coadministration of phenytoin with a dose bioequivalent to 34 mg nisoldipine extended-release tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels. Coadministration of nisoldipine extended-release tablets with phenytoin should be avoided and alternative antihypertensive therapy should be considered. Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant. Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.
Source: FDA prescribing information (DailyMed). Set ID: a52b773a-44f9-442f-a4be-39f79a558bd2. SPL document ID: cef2c469-9a1b-46f3-b08f-57ea2876311f. Label effective date: June 8, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.